![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Fibroma - 265 Studies Found
Recruiting |
: National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) : Aggressive Fibromatosis : 2016-07-15 :
|
Active, not recruiting |
: Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis :
|
Active, not recruiting |
: Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets : Desmoid Type-fibromatosis : 2015-01-28 : Drug: Toremifene Patients will receive 60 mg daily and then 180 daily in case of progression |
Recruiting |
: Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients : Desmoid-type Fibromatosis : 2015-01-28 : Other: Observational approach Patients will be placed under wait and see approach without any specific t |
Active, not recruiting |
: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis : Desmoid-Type Fibromatosis : 2014-02-17 :
|
Completed |
: Study to Evaluate Imatinib in Desmoid Tumors :
|
Completed |
: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis : Desmoid Tumor : 2006-02-06 : Drug: imatinib mesylate |
Recruiting |
: 18F-FES PET/CT in Imaging Patients With Desmoid Tumors :
|
Withdrawn |
: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors :
: 2009-09-15 : Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w |
Active, not recruiting |
: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma :
: 2009-06-25 : Drug: Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months |